Atlas
Back to Pharma Services
Investment Banker·Pharma Services

Stuart Smith

Partner, Healthcare Practice at Centerview Partners

New York, NY, USA

SS
LinkedIn
Why they matter

One of the most senior healthcare services bankers on Wall Street, with three decades of pattern-recognition across CDMO, CRO, PBM, and services roll-ups and consolidations.

Background

Stuart Smith is a Partner in the Healthcare Practice at Centerview Partners in New York, which he joined in August 2016 after 17 years at Credit Suisse, where he was Global Head of the Healthcare Group. He holds a J.D. from the University of Connecticut School of Law, an MBA from Columbia Business School, and a B.S. from Franklin and Marshall College. Over a 30+ year career he has advised on more than $300 billion of healthcare transactions, with deep expertise in managed care, hospitals, PBMs/specialty pharmacy, distribution, CROs, clinical labs, and physician outsourcing.

Notable deals

  • 2006
    Advised HCA on its $33 billion sale to a financial sponsor consortium
  • 2011
    Advised Genzyme on its $20 billion sale to Sanofi
  • 2017
    Advised PPD on its $9 billion recapitalization and sale of control to Hellman & Friedman
  • 2018
    Advised Express Scripts on its $66 billion sale to Cigna

Call-prep brief

Background

  • Partner, Healthcare Practice at Centerview Partners (joined Aug. 2016); prior 17 years as Global Head of Healthcare Investment Banking at Credit Suisse.
  • 30+ years in healthcare banking; earlier stints at Alex. Brown & Sons and Lehman Brothers Kuhn, Loeb.
  • J.D. (Univ. of Connecticut), MBA (Columbia), B.S. (Franklin & Marshall) — unusual law-to-banking path worth probing.

Current focus

  • Healthcare services: managed care, hospitals, PBMs/specialty pharmacy, distribution, CROs, clinical labs, physician outsourcing — directly adjacent to pharma services/CDMO deal flow.
  • Has advised on $300B+ of transactions, including Express Scripts/Cigna ($66B, 2018), HCA's sponsor buyout ($33B, 2006), Genzyme/Sanofi ($20B, 2011), and PPD's recap with Hellman & Friedman ($9B, 2017).

What they care about

  • Scaled, defensible services platforms with regulatory or reimbursement complexity that command premium multiples.
  • Sponsor consortium dynamics and control transitions in large-cap healthcare services deals.

Recent moves / sensitivities

  • Long Centerview tenure (10 years) suggests deep continuity of client relationships — useful but may also mean conflicts with active mandates in the CDMO/pharma services space.
  • As an active sell-side/M&A advisor, he cannot share confidential deal information — frame outreach around market perspective, not live processes.

Questions to ask

  1. Where is strategic and sponsor buyer appetite currently concentrated within pharma services/CDMO — bolt-ons vs. platform-scale deals?
  2. How are financing conditions and rate expectations shaping sponsor consortium structures compared to the HCA-era deals he led?
  3. What operational or regulatory attributes are commanding the largest valuation premiums in recent CRO/CDMO transactions he's seen?

Outreach draft

Subject
Perspective on pharma services / CDMO M&A
Hi Stuart, I'm reaching out from a private equity firm focused on the pharma services and CDMO sector. Given your work advising on landmark healthcare services transactions — Express Scripts/Cigna, PPD's recapitalization, and others — I'd value your read on where strategic and sponsor interest is heading in outsourced pharma services right now. Would you be open to a brief call in the next couple of weeks to share your perspective on deal structures, valuation trends, and where you see consolidation opportunities in the space? Happy to work around your schedule. Thanks in advance, [Your Name]

Linked companies

Sources